Literature DB >> 24252300

The pimple sign of progressive supranuclear palsy syndrome.

Hugo Botha1, Jennifer L Whitwell2, Ajay Madhaven2, Matthew L Senjem3, Val Lowe2, Keith A Josephs4.   

Abstract

BACKGROUND: Some patients with progressive supranuclear palsy syndrome (PSPS) demonstrate a focal area of midbrain hypometabolism on FDG-PET scans which we call the 'pimple sign'. We assessed its association with midbrain atrophy, its reliability and its ability to differentiate PSPS from corticobasal syndrome (CBS) and multiple system atrophy (MSA).
METHODS: We identified 67 patients with PSPS, CBS or MSA who had volumetric MRI as well as FDG-PET imaging. Midbrain volume was measured and expressed as a percentage of total intracranial volume. Two independent, blinded specialists rated the 'pimple sign' on FDG-PET as 'absent', 'possible' or 'definite'. Midbrain volumes were compared across these groups and reliability assessed with the kappa statistic. Sensitivity and specificity were calculated using CBS and MSA patients as controls.
RESULTS: Midbrain volume was decreased in the 'definite' group compared to the 'absent' and 'possible' groups (p = 0.0036). Inter-rater reliability for the pimple sign was high (κ = 0.90). A 'definite pimple sign' had a high specificity (100%) but low sensitivity (29%) for PSPS, whilst the presence of a possible or definite sign had a sensitivity of 79%.
CONCLUSION: The 'pimple sign' of PSPS is associated with midbrain atrophy, and may be helpful in differentiating PSPS from CBS and MSA.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  FDG-PET; Midbrain atrophy; PSPS; Parkinsonism; Pimple sign

Mesh:

Substances:

Year:  2013        PMID: 24252300     DOI: 10.1016/j.parkreldis.2013.10.023

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  19 in total

Review 1.  Current Understanding of Neurodegenerative Diseases Associated With the Protein Tau.

Authors:  Keith A Josephs
Journal:  Mayo Clin Proc       Date:  2017-08       Impact factor: 7.616

2.  MRI Outperforms [18F]AV-1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy.

Authors:  Jennifer L Whitwell; Nirubol Tosakulwong; Christopher G Schwarz; Hugo Botha; Matthew L Senjem; Anthony J Spychalla; J Eric Ahlskog; David S Knopman; Ronald C Petersen; Clifford R Jack; Val J Lowe; Keith A Josephs
Journal:  Mov Disord       Date:  2018-11-23       Impact factor: 10.338

3.  Progressive Supranuclear Palsy and Corticobasal Degeneration.

Authors:  David G Coughlin; Dennis W Dickson; Keith A Josephs; Irene Litvan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  The evolution of primary progressive apraxia of speech.

Authors:  Keith A Josephs; Joseph R Duffy; Edythe A Strand; Mary M Machulda; Matthew L Senjem; Jeffrey L Gunter; Christopher G Schwarz; Robert I Reid; Anthony J Spychalla; Val J Lowe; Clifford R Jack; Jennifer L Whitwell
Journal:  Brain       Date:  2014-08-11       Impact factor: 13.501

Review 5.  Key emerging issues in progressive supranuclear palsy and corticobasal degeneration.

Authors:  Keith A Josephs
Journal:  J Neurol       Date:  2015-02-21       Impact factor: 4.849

6.  Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy.

Authors:  Richard M Tsai; Iryna Lobach; Jee Bang; Jennifer L Whitwell; Matthew L Senjem; Clifford R Jack; Howard Rosen; Bruce Miller; Adam L Boxer
Journal:  Parkinsonism Relat Disord       Date:  2016-04-24       Impact factor: 4.891

7.  FDG-PET in pathologically confirmed spontaneous 4R-tauopathy variants.

Authors:  Nicholas Zalewski; Hugo Botha; Jennifer L Whitwell; Val Lowe; Dennis W Dickson; Keith A Josephs
Journal:  J Neurol       Date:  2014-02-04       Impact factor: 4.849

Review 8.  New Imaging Markers for Movement Disorders.

Authors:  Christine Ghadery; Antonio P Strafella
Journal:  Curr Neurol Neurosci Rep       Date:  2018-04-03       Impact factor: 5.081

Review 9.  Progressive supranuclear palsy (PSP): Richardson syndrome and other PSP variants.

Authors:  G Lopez; K Bayulkem; M Hallett
Journal:  Acta Neurol Scand       Date:  2016-01-06       Impact factor: 3.209

10.  An Evaluation of the Progressive Supranuclear Palsy Speech/Language Variant.

Authors:  Jennifer L Whitwell; Chase A Stevens; Joseph R Duffy; Heather M Clark; Mary M Machulda; Edythe A Strand; Peter R Martin; Rene L Utianski; Hugo Botha; Anthony J Spychalla; Matthew L Senjem; Christopher G Schwarz; Clifford R Jack; Farwa Ali; Anhar Hassan; Keith A Josephs
Journal:  Mov Disord Clin Pract       Date:  2019-05-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.